Company name: Pure Global Cannabis
Description: Producer of cannabis-infused products for medical and adult-use markets. The company utilizes pharmaceutical technologies to harness the therapeutic properties of cannabis to produce products such as dried flowers, soft capsules and gels, seedlings and clones, vape pen cartridges, topicals, sublingual strips, transdermal patches, beverages, cannabis oils, and other related products.
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
Start up capital raised (USD Million):
Business status: Profitable
Ownership: Publicly Held
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Earnings before interest, tax, depreciation and amortization (EBITDA):
Financing Status: The company acquired Royal Sapphire (TSX: RSL) through a reverse merger, resulting in the combined entity trading on the TSX Stock Exchange under the ticker symbol PURE on July 06, 2018.
Number of active investors:
Profile last updated: 21-Sep-2018
Last known valuation:
Last known valuation date: